BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Raised to Sell at BidaskClub
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Tuesday, August 1st.
Other analysts have also recently issued research reports about the stock. Noble Financial reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Sunday, May 28th. Zacks Investment Research raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Monday, May 1st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of BioCryst Pharmaceuticals in a research report on Wednesday, April 12th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. BioCryst Pharmaceuticals presently has an average rating of “Hold” and an average price target of $8.00.
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) traded up 5.10% on Tuesday, hitting $4.53. The company’s stock had a trading volume of 824,839 shares. BioCryst Pharmaceuticals has a one year low of $3.75 and a one year high of $9.25. The stock has a 50-day moving average price of $5.36 and a 200 day moving average price of $6.28. The firm’s market cap is $364.34 million.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.02. BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The firm had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $5.79 million. During the same period last year, the company earned ($0.22) EPS. The business’s quarterly revenue was down 35.4% on a year-over-year basis. Equities research analysts predict that BioCryst Pharmaceuticals will post ($0.72) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Raised to Sell at BidaskClub” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/12/biocryst-pharmaceuticals-inc-nasdaqbcrx-rating-increased-to-sell-at-bidaskclub-updated.html.
Institutional investors have recently bought and sold shares of the company. Comerica Bank boosted its position in BioCryst Pharmaceuticals by 18.8% in the fourth quarter. Comerica Bank now owns 16,105 shares of the biotechnology company’s stock worth $100,000 after buying an additional 2,552 shares during the last quarter. Legal & General Group Plc boosted its position in BioCryst Pharmaceuticals by 4.9% in the second quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock worth $102,000 after buying an additional 860 shares during the last quarter. Principal Financial Group Inc. raised its stake in BioCryst Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock worth $111,000 after buying an additional 45 shares during the period. Fox Run Management L.L.C. acquired a new stake in BioCryst Pharmaceuticals during the second quarter worth about $126,000. Finally, Janney Montgomery Scott LLC raised its stake in BioCryst Pharmaceuticals by 4.7% in the second quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock worth $185,000 after buying an additional 1,500 shares during the period. 84.49% of the stock is owned by hedge funds and other institutional investors.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Stock Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.